Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
Werewolf Therapeutics (NASDAQ: HOWL) announced its participation in the KidneyCAN 7th Annual Kidney Cancer Research Summit on July 17-18, 2025, in Boston. Chief Medical Officer Dr. Randi Isaacs will present on the company's WTX-124, a tumor-activated IL-2 INDUKINE molecule, during the Biotech Showcase session.
The presentation will highlight how WTX-124 aims to improve upon traditional high-dose IL-2 therapy for renal cell carcinoma (RCC) by maximizing anti-tumor activity while reducing systemic side effects. The company's ongoing "Full Moon Moment" campaign supports clinical trials, with notable success including a patient with cutaneous squamous cell carcinoma achieving remission for over a year.
Werewolf Therapeutics (NASDAQ: HOWL) ha annunciato la sua partecipazione al KidneyCAN 7° Summit Annuale sulla Ricerca sul Cancro del Rene, che si terrà il 17-18 luglio 2025 a Boston. Il Chief Medical Officer, Dr. Randi Isaacs, presenterà il WTX-124 dell'azienda, una molecola INDUKINE IL-2 attivata dal tumore, durante la sessione Biotech Showcase.
La presentazione illustrerà come WTX-124 miri a migliorare la terapia tradizionale con IL-2 ad alto dosaggio per il carcinoma a cellule renali (RCC), massimizzando l'attività antitumorale e riducendo gli effetti collaterali sistemici. La campagna in corso "Full Moon Moment" supporta gli studi clinici, con un successo significativo, tra cui un paziente con carcinoma squamoso cutaneo in remissione da oltre un anno.
Werewolf Therapeutics (NASDAQ: HOWL) anunció su participación en la 7ª Cumbre Anual de Investigación sobre el Cáncer de Riñón de KidneyCAN, que se celebrará el 17 y 18 de julio de 2025 en Boston. La directora médica, la Dra. Randi Isaacs, presentará el WTX-124 de la compañía, una molécula INDUKINE de IL-2 activada por tumores, durante la sesión Biotech Showcase.
La presentación destacará cómo WTX-124 busca mejorar la terapia tradicional de IL-2 en dosis altas para el carcinoma de células renales (RCC), maximizando la actividad antitumoral y reduciendo los efectos secundarios sistémicos. La campaña en curso "Full Moon Moment" apoya los ensayos clínicos, con éxitos notables, incluyendo un paciente con carcinoma de células escamosas cutáneo que ha logrado la remisión por más de un año.
Werewolf Therapeutics (NASDAQ: HOWL)는 2025년 7월 17일~18일 보스턴에서 열리는 KidneyCAN 제7회 연례 신장암 연구 서밋에 참여한다고 발표했습니다. 최고 의료 책임자인 Dr. Randi Isaacs가 Biotech Showcase 세션에서 회사의 WTX-124라는 종양 활성화 IL-2 INDUKINE 분자에 대해 발표할 예정입니다.
발표에서는 WTX-124가 신세포암(RCC)에 대한 기존 고용량 IL-2 치료법을 개선하여 항종양 활성을 극대화하고 전신 부작용을 줄이는 방법을 강조할 것입니다. 회사의 진행 중인 "Full Moon Moment" 캠페인은 임상 시험을 지원하며, 그 중 피부 편평세포암 환자가 1년 이상 관해 상태를 유지하는 등 주목할 만한 성과를 보이고 있습니다.
Werewolf Therapeutics (NASDAQ : HOWL) a annoncé sa participation au 7e Sommet annuel KidneyCAN sur la recherche sur le cancer du rein, qui se tiendra les 17 et 18 juillet 2025 à Boston. Le directeur médical, le Dr Randi Isaacs, présentera le WTX-124 de la société, une molécule INDUKINE IL-2 activée par la tumeur, lors de la session Biotech Showcase.
La présentation mettra en lumière comment le WTX-124 vise à améliorer la thérapie traditionnelle par IL-2 à haute dose pour le carcinome à cellules rénales (RCC), en maximisant l'activité antitumorale tout en réduisant les effets secondaires systémiques. La campagne en cours "Full Moon Moment" soutient les essais cliniques, avec un succès notable, notamment un patient atteint d'un carcinome épidermoïde cutané en rémission depuis plus d'un an.
Werewolf Therapeutics (NASDAQ: HOWL) gab seine Teilnahme am KidneyCAN 7. jährlichen Kidney Cancer Research Summit am 17. und 18. Juli 2025 in Boston bekannt. Chief Medical Officer Dr. Randi Isaacs wird während der Biotech Showcase-Session das WTX-124 des Unternehmens vorstellen, ein tumoraktiviertes IL-2 INDUKINE-Molekül.
Die Präsentation wird hervorheben, wie WTX-124 die herkömmliche Hochdosis-IL-2-Therapie für Nierenzellkarzinom (RCC) verbessern soll, indem es die antitumorale Aktivität maximiert und gleichzeitig systemische Nebenwirkungen reduziert. Die laufende "Full Moon Moment"-Kampagne des Unternehmens unterstützt klinische Studien, mit bemerkenswertem Erfolg, darunter ein Patient mit kutanem Plattenepithelkarzinom, der seit über einem Jahr in Remission ist.
- None.
- None.
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Randi Isaacs, M.D., Chief Medical Officer, will speak at the upcoming KidneyCAN 7th Annual Kidney Cancer Research Summit taking place July 17-18 in Boston, Massachusetts.
The presentation will focus on Werewolf’s innovative approach to harnessing conditionally-activated cytokines designed to selectively activate immune responses within tumors. It will cover early clinical findings from the development of WTX-124, a tumor-activated IL-2 INDUKINE molecule. While high-dose IL-2 is a proven therapy for renal cell carcinoma (RCC), among other solid tumors, its use is limited by severe toxicity. Dr. Isaacs will highlight how the WTX-124 strategy aims to improve the therapeutic index, maximizing anti-tumor activity in immunotherapy-sensitive tumors like RCC while reducing systemic side effects. Presentation details:
Session: 8 – Biotech Showcase
Title: Unmasking the Potential of Conditionally-Activated Cytokines: Lessons Learned from the Early Clinical Development of WTX-124, a Tumor-Activated IL-2 INDUKINE Molecule
Date: Friday, July 18, 2025
Time: 2:45pm ET
Werewolf continues to conduct the “Full Moon Moment,” an awareness campaign supporting its ongoing national trials, including the WTX-124 IL-2 INDUKINE molecule, which is actively enrolling patients with advanced or metastatic RCC, among other solid tumors. Multiple responses have been reported, including a patient with cutaneous squamous cell carcinoma who has been in remission for more than a year. The campaign highlights the potential for such outcomes and encourages patients to explore new options. “Full Moon Moment” represents how INDUKINE™ molecules activate their tumor-killing power within the tumor microenvironment. Learn more about Werewolf’s current WTX-124 clinical trial here.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf’s strategy, future operations, prospects, plans, and objectives of management; the potential activity and efficacy of product candidates in preclinical studies and clinical trials; and the anticipated safety profile of product candidates constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “design,” “designed to,” “engineered,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “positioning itself to,” “potential,” “predict,” “project,” “promise,” “should,” “target,” “will,” “working to,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, and the initiation and completion of preclinical studies and clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the future results of the trial and future clinical trials; as well as the risks and uncertainties identified in the “Risk Factors” section of the Company’s most recent Form 10-Q filed with the Securities and Exchange Commission (SEC), and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com
FAQ
When is Werewolf Therapeutics (HOWL) presenting at the KidneyCAN Kidney Cancer Research Summit 2025?
What is WTX-124 and how does it work for kidney cancer treatment?
What clinical results has Werewolf Therapeutics reported for WTX-124?
What types of cancer is Werewolf Therapeutics' WTX-124 being tested for?
